<DOC>
	<DOCNO>NCT00142350</DOCNO>
	<brief_summary>To investigate superiority combination irinotecan cisplatin non-inferiority S-1 compare continuous infusion 5-FU advanced gastric cancer</brief_summary>
	<brief_title>A Study 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone Advanced Gastric Cancer</brief_title>
	<detailed_description>From result previous phase III study ( JCOG9205 ) , continuous infusion 5-fluorouracil remain control arm study . This study investigate superiority combination irinotecan plus cisplatin non-inferiority S-1 , oral fluoropyrimidine , compare continuous infusion 5-fluorouracil point overall survival , plan number enrol patient 690 ( 230/arm ) .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1. unresectable recurrent histologically prove gastric cancer 2. adequate oral intake 3. age 20 old 75 young 4 . Performance Status ( ECOG ) :0 , 1 , 2 5. measurable unmeasurable lesion 6. preserve organ function 7. severe medical condition 8. prior chemotherapy gastric cancer 9. write informed consent 1. patient mark infection inflammation 2. patient severe peritoneal metastasis 3. patient massive pleural effusion 4. patient metastasis CNS 5. patient diarrhea 4 time per day 6. patient severe medical condition 7. patient concurrent malignancy affect survival adverse event 8. pregnant nursing patient intent bear baby 9. patient evaluate inadequate attend doctor 10. patient require nutritional support</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>5-fluorouracil</keyword>
	<keyword>irinotecan</keyword>
	<keyword>cisplatin</keyword>
	<keyword>S-1</keyword>
	<keyword>advanced recurrent gastric cancer</keyword>
</DOC>